Abstract
Background: Early findings on the use of tamoxifen or raloxifene as prophylaxis against breast cancer have been mixed; we update available data and overview the combined results. Methods: All five randomised prevention trials comparing tamoxifen or raloxifene with placebo were included. Relevant data on contralateral breast tumours and side-effects were included from an overview of adjuvant trials of tamoxifen versus control. Findings: The tamoxifen prevention trials showed a 38% (95% Cl 28-46; p
Original language | English |
---|---|
Pages (from-to) | 296-300 |
Number of pages | 5 |
Journal | Lancet |
Volume | 361 |
Issue number | 9354 |
DOIs | |
Publication status | Published - Jan 25 2003 |
ASJC Scopus subject areas
- Medicine(all)